Overabundant FANCD2, alone and combined with NQO1, is a sensitive marker of adverse prognosis in breast cancer

Annals of Oncology

Volumn 24, Issue 11, 2013, Pages 2780-2785

  Fagerholm, R ^a   Sprott, K ^b   Heikkinen, T ^a   Bartkova, J ^c   Heikkila P ^d   Aittomaki K ^d   Bartek, J ^c,e   Weaver, D ^b   Nevanlinna, H ^a   Blomqvist, C ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b On Q ity   (United States)

^c DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^d UNIVERSITY OF HELSINKI   (Finland)

^e PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Breast cancer; Dna repair; Fancd2; Nqo1; Prognosis

Indexed keywords

BRCA1 PROTEIN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FANCONI ANEMIA GROUP D2 PROTEIN; NAD(P)H:QUINONE DEHYDROGENASE 1; NUCLEIC ACID BINDING PROTEIN; OXIDOREDUCTASE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN XPF; RAD51 PROTEIN; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DOWN REGULATION; EXCISION REPAIR; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MICROARRAY ANALYSIS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; UPREGULATION;

BREAST CANCER; DNA REPAIR; FANCD2; NQO1; PROGNOSIS;

BREAST NEOPLASMS; DNA REPAIR; FANCONI ANEMIA COMPLEMENTATION GROUP D2 PROTEIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NAD(P)H DEHYDROGENASE (QUINONE); PROGNOSIS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84887068678     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt290     Document Type: Article

References (29)

1. Moynahan ME, Chiu JW, Koller BH et al. Brca1 controls homology-directed DNA repair. Mol Cell 1999; 4: 511-518.
2. Snouwaert JN, Gowen LC, Latour AM et al. BRCA1 Deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a brca1 transgene. Oncogene 1999; 18: 7900-7907.
3. Howlett NG, Taniguchi T, Olson S et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002; 297: 606-609.
4. Rahman N, Seal S, Thompson D et al. PALB2, Which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007; 39: 165-167.
5. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009; 461: 1071-1078.
6. Cass I, Baldwin RL, Varkey T et al. Improved survival in women with BRCAassociated ovarian carcinoma. Cancer 2003; 97: 2187-2195.
7. Silver DP, Richardson AL, Eklund AC et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010; 28: 1145-1153.
8. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature 2012; 481: 287-294.
9. Luo X, Kraus WL. On PAR with PARP: cellular stress signaling through poly(ADPribose) and PARP-1. Genes Dev 2012; 26: 417-432.
10. Maynard S, Schurman SH, Harboe C et al. Base excision repair of oxidative DNA damage and association with cancer and aging. Carcinogenesis 2009; 30: 2-10.
11. Kim DH, Kundu JK, Surh YJ. Redox modulation of p53: mechanisms and functional significance. Mol Carcinog 2011; 50: 222-234.
12. Ladelfa MF, Toledo MF, Laiseca JE et al. Interaction of p53 with tumor suppressive and oncogenic signaling pathways to control cellular reactive oxygen species production. Antioxid Redox Signal 2011; 15: 1749-1761.
13. Li J, Du W, Maynard S et al. Oxidative stress-specific interaction between FANCD2 and FOXO3a. Blood 2010; 115: 1545-1548.
14. Beyer RE, Segura-Aguilar J, Di Bernardo S et al. The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems. Proc Natl Acad Sci U S A 1996; 93: 2528-2532.
15. Asher G, Tsvetkov P, Kahana C et al. A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. Genes Dev 2005; 19: 316-321.
16. Ross D, Zhou H, Siegel D. Benzene toxicity: The role of the susceptibility factor NQO1 in bone marrow endothelial cell signaling and function. Chem Biol Interact 2011; 192: 145-149.
17. Siegel D, Kepa JK, Ross D. NAD(P)H:Quinone Oxidoreductase 1 (NQO1) localizes to the mitotic spindle in human cells. PLoS One 2012; 7: e44861.
18. Tommiska J, Eerola H, Heinonen M et al. Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 2005; 11: 5098-5103.
19. Jamshidi M, Bartkova J, Greco D et al. NQO1 Expression correlates inversely with NFkappaB activation in human breast cancer. Breast Cancer Res Treat 2012; 132: 955-968.
20. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57.
21. Jantzen SG, Sutherland BJ, Minkley DR et al. GO trimming: systematically reducing redundancy in large gene ontology datasets. BMC Res Notes 2011; 4: 267.
22. van der Groep P, Hoelzel M, Buerger H et al. Loss of expression of FANCD2 protein in sporadic and hereditary breast cancer. Breast Cancer Res Treat 2008; 107: 41-47.
23. Nijman SM, Huang TT, Dirac AM et al. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol Cell 2005; 17: 331-339.
24. Garcia-Higuera I, Taniguchi T, Ganesan S et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 2001; 7: 249-262.
25. Moldovan GL, D'Andrea AD. How the fanconi anemia pathway guards the genome. Annu Rev Genet 2009; 43: 223-249.
26. Holzel M, van Diest PJ, Bier P et al. FANCD2 Protein is expressed in proliferating cells of human tissues that are cancer-prone in Fanconi anaemia. J Pathol 2003; 201: 198-203.
27. Mah LJ, El-Osta A, Karagiannis TC. gammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia 2010; 24: 679-686.
28. Deans AJ, West SC. DNA Interstrand crosslink repair and cancer. Nat Rev Cancer 2011; 11: 467-480.
29. Shen X, Do H, Li Y et al. Recruitment of Fanconi anemia and breast cancer proteins to DNA damage sites is differentially governed by replication. Mol Cell 2009; 35: 716-723.